Products for Research Use Only
RegisterLogin

Volixibat

CAT: 0804-HY-101190-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-101190-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH) [1][2].
CAS Number
1025216-57-2
Product Name Alternative
SHP626; LUM002
UNSPSC
12352005
Target
Apical Sodium-Dependent Bile Acid Transporter
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/volixibat.html
Solubility
10 mM in DMSO
Smiles
O=C(N[C@H]1[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(O)=O)O1)O)OCC2=CC=CC=C2)O)NC3=CC=CC([C@H](C4=CC(N(C)C)=CC=C45)[C@@H](O)[C@](CC)(CCCC)CS5(=O)=O)=C3
Molecular Formula
C38H51N3O12S2
Molecular Weight
805.95
References & Citations
[1]Salic K, et al. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolicaspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One. 2019 Jun 24;14 (6) :e0218459.|[2]Palmer M, et al. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2018 Mar 16;19 (1) :10.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
T17236Volixibat
MBS3601837Volixibat potassium

Popular Products